Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
14 studies found for:    17021318 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Drug: ranibizumab
2 Unknown  Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
Condition: Exudative Age-related Macular Degeneration
Intervention: Drug: ranibizumab
3 Completed
Has Results
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Condition: Exudative Age-related Macular Degeneration
Intervention: Drug: ranibizumab
4 Terminated
Has Results
Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Interventions: Drug: Ranibizumab (Lucentis);   Drug: 0.5mg ranibizumab
5 Completed
Has Results
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
Conditions: Exudative Age-related Macular Degeneration;   Polypoidal Choroidal Vasculopathy
Intervention: Drug: aflibercept
6 Completed Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START
Condition: Neovascular Age-related Macular Degeneration of All Subtypes
Intervention: Procedure: Intravitreal injection
7 Completed A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: rhuFab V2 (ranibizumab)
8 Active, not recruiting Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
Condition: Macular Degeneration
Intervention: Drug: 0.5mg ranibizumab
9 Completed Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion
Condition: Neovascular Age-related Macular Degeneration
Intervention: Procedure: Intravitreal expansile gas and ranibizumab injection
10 Recruiting Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD
Condition: Neovascular Age-related Macular Degeneration
Interventions: Procedure: 1+PRN;   Procedure: 3+PRN;   Drug: Ranibizumab
11 Completed Study for Recalcitrant Age Related Macular Degeneration
Condition: Age Related Macular Degeneration
Intervention: Drug: aflibercept 2.0 mg
12 Withdrawn Ranibizumab for Neovascularization in Sickle Cell Retinopathy
Conditions: Sickle Cell Anemia;   Retinopathy
Intervention: Drug: Ranibizumab
13 Recruiting Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
Condition: Radiation Retinopathy
Interventions: Drug: 0.5 mg ranibizumab;   Procedure: Targeted Retinal Photocoagulation
14 Unknown  Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration
Conditions: Macular Degeneration;   Visual Acuity
Intervention: Drug: Ranibizumab

Study has passed its completion date and status has not been verified in more than two years.